RxDoctor Payments Data

Natesha Vaillancourt, APRN

Advanced Practice Midwife · Ocala, FLNPI 1124161559

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Astellas Pharma US Inc at 25.8% of the total. 2025 is the largest year on record at $450, 5.5 times the $82 reported in 2021.

$1,104in general payments, 2019–2025

Across 51 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$285
  • AbbVie$196
  • Sumitomo Pharma America, Inc.$163
  • Bayer$55
  • Myovant Sciences Inc.$50
  • Organon$44
  • plus $311 from 12 others

What the payments were for

  • Food & beverage$1,01192%
  • Education$938%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,104 in reported general payments places this provider in the 85th percentile of 579 advanced practice midwife providers in Florida.

See all advanced practice midwife providers in Florida

Medicare billing

Part B allowed, 2024
$15,287
Medicare patients
136
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$5,416
Estradiol65$2,770
Clobetasol Propionate33$1,323
Metronidazole14$449
Fluconazole26$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$285$5,41612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 579 advanced practice midwife providers in Florida.

Other advanced practice midwife in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →